Report overview
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report contains market size and forecasts of CAR T-Cell Therapy in Global, including the following market information:
Global CAR T-Cell Therapy Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global CAR T-Cell Therapy market was valued at 1770.5 million in 2022 and is projected to reach US$ 10330 million by 2030, at a CAGR of 28.7% during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
CD19 - Targeted Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of CAR T-Cell Therapy include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline) and Sorrento Therapeutics(Pipeline), etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the CAR T-Cell Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR T-Cell Therapy Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global CAR T-Cell Therapy Market Segment Percentages, by Type, 2022 (%)
CD19 - Targeted
BCMA - Targeted
Global CAR T-Cell Therapy Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global CAR T-Cell Therapy Market Segment Percentages, by Application, 2022 (%)
Lymphoma
Multiple Myeloma
Global CAR T-Cell Therapy Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global CAR T-Cell Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR T-Cell Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies CAR T-Cell Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
